Moderna's Trading Volume Drops 31.52% to $189 Million as Stock Price Falls 1.77% Despite FDA Approval Expansion for RSV Vaccine

On June 17, 2025, Moderna's trading volume reached $189 million, marking a 31.52% decrease from the previous day. The company's stock price fell by 1.77%, extending its losing streak to four consecutive days, with a total decline of 7.96% over the past four days.

Moderna has received significant regulatory approvals for its RSV vaccine, mRESVIA. The U.S. FDA has expanded the approval of mRESVIA for use in high-risk adults aged 18-59, including those with medical conditions that increase their risk for RSV disease. This expansion follows the initial approval of the vaccine, which was granted last year. The FDA's decision to broaden the vaccine's indication is a positive development for Moderna, as it opens up a larger market for the vaccine and reinforces the company's position in the respiratory vaccine market.

Moderna is also actively working on expanding the use of mRESVIA in pediatric populations. This effort, if successful, could further boost the company's revenue and market share in the RSV vaccine market. The company's focus on expanding the use of its RSV vaccine demonstrates its commitment to addressing the unmet medical needs of high-risk populations and improving public health outcomes.